flutamide การใช้

• The non-steroidal antiandrogen flutamide was first reported in 1967.
• Flutamide was followed by nilutamide in 1989 and bicalutamide in 1995.
• Flutamide has a fairly short half-life of 5 6 hours.
• Dihydrotestosterone increased the number of BrdU cells, while flutamide inhibited these cells.
• Other medications include ketoconazole, and in female androgenic alopecia spironolactone and flutamide.
• Flutamide became the first NSAA to be tested clinically.
• It is the major active metabolite of flutamide.
• In contrast to flutamide and nilutamide, no specific complications have been linked to bicalutamide.
• Schering-Plough, based in Madison, New Jersey, sells flutamide under the brand Eulexin.
• The mechanism of action of flutamide-induced hepatotoxicity is thought to be due to mitochondrial toxicity.
• The drug treatment studied involved flutamide pills three times daily with periodic injections of either leuprolide acetate or goserelin.
• These compounds are similar in chemical structure to nilutamide, which is related to flutamide, bicalutamide, and enzalutamide.
• Inhibition of complex I has been implicated in hepatotoxicity associated with a variety of drugs, for instance flutamide and nefazodone.
• Like flutamide and bicalutamide, nilutamide is able to cross the blood-brain-barrier and has central antiandrogen actions.
• Flutamide-treated survivin mutant-transduced cells were shown to significantly increase apoptosis by double that of Flutamide treatment alone.
• Flutamide-treated survivin mutant-transduced cells were shown to significantly increase apoptosis by double that of Flutamide treatment alone.
• Several studies have observed complete clearing of acne with flutamide in women, and similar or benefits would be expected with bicalutamide.
• The combination of paracetamol ( acetaminophen ) and flutamide may result in additive to synergistic hepatotoxicity, indicating a potential drug interaction.
• Next, with the addition of Flutamide ( an antiandrogen ) to the cells, survivin levels were observed to significantly decrease.
• The patent protection of all three of the first-generation has expired and flutamide and bicalutamide are both available as relatively inexpensive generics.